アトピー性皮膚炎市場 - KOLの考察

当レポートでは、アトピー性皮膚炎市場について調査分析し、上市済みの治療法とパイプライン治療法の将来性に対するKOLの考察を提供しています。

目次

エグゼクティブサマリー

アトピー性皮膚炎の将来の治療パラダイム

調査目的

現在の治療戦略

• Dupixent (dupilumab; Sanofi/Regeneron)
  • 重要な考察のまとめ
• Adbry/Adtralza (tralokinumab; LEO Pharma)
  • 重要な考察のまとめ
• Olumiant (baricitinib; Lilly/Incyte)
  • 重要な考察のまとめ
• Cibinqo (abrocitinib; Pfizer)
  • 重要な考察のまとめ
• Rinvoq (upadacitinib; AbbVie)
  • 重要な考察のまとめ

後期パイプラインプログラム

• Lebrikizumab (Lilly/Almirall)
  • 重要な考察のまとめ
• Nemolizumab (Galderma/Chugai/Maruho)
  • 重要な考察のまとめ
• Etrasimod (Pfizer)
  • 重要な考察のまとめ
• Ivarmacitinib (SHR 0302; Reistone Biopharma)
  • 重要な考察のまとめ
• Rocatinlimab (Kyowa Kirin/Amgen)
  • 重要な考察のまとめ

治療に影響を与える初期段階の開発とその他の要因

• 専門家たちは、アトピー性皮膚炎の治療法となる可能性のあるB 244に圧倒されています。

付録

What clinical advantages underpin KOLs' opinion that Eli Lilly/Almirall's anti-IL13 lebrikizumab has the potential to disrupt the treatment paradigm and which current therapies could be impacted? Why are experts excited about Kyowa Kirin/Amgen's novel anti-OX40 rocatinlimab and where do they see it delivering value? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area.

Table of Contents

Executive summary (9)

Future treatment paradigm for atopic dermatitis

Research objectives (1)

Current treatment strategies (43)

• Dupixent (dupilumab; Sanofi/Regeneron) (10)
  • Key insights summary (10)
• Adbry/Adtralza (tralokinumab; LEO Pharma) (11)
  • Key insights summary (11)
• Olumiant (baricitinib; Lilly/Incyte) (8)
  • Key insights summary (8)
• Cibinqo (abrocitinib; Pfizer) (8)
  • Key insights summary (8)
• Rinvoq (upadacitinib; AbbVie) (6)
  • Key insights summary (6)

Late-stage pipeline programmes (34)

• Lebrikizumab (Lilly/Almirall) (6)
  • Key insights summary (6)
• Nemolizumab (Galderma/Chugai/Maruho) (6)
  • Key insights summary (6)
• Etrasimod (Pfizer) (7)
  • Key insights summary (7)
• Ivarmacitinib (SHR 0302; Reistone Biopharma) (6)
  • Key insights summary (6)
• Rocatinlimab (Kyowa Kirin/Amgen) (9)
  • Key insights summary (9)

Earlier-stage developments and other factors impacting treatment (12)

• Experts are underwhelmed by B 244 as a potential therapy for atopic dermatitis (11)
  • KOLs regard lirentelimab as interesting but question whether mast cells and eosinophils play a central role in atopic dermatitis (3)
  • LP 0145 has potential but some experts believe bispecific inhibition or selecting IL22-expressing population may hold more benefit (1)
  • Microbiome involvement in preventing atopic dermatitis is a formidable goal; KOLs agree very limited progress being made (2)
  • New topical formulations will be welcomed in the US; European KOLs are sceptical that they will reach the European market due to high cost (3)

Appendix (4)

• KOL details (4)
  • US KOLs (1)
  • European KOLs (2)